Trv Gp V LLC Purchases Shares of 6,215,591 Septerna, Inc. (NASDAQ:SEPN)

TRV GP V LLC purchased a new stake in Septerna, Inc. (NASDAQ:SEPN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,215,591 shares of the company's stock, valued at approximately $142,337,000. Septerna makes up about 48.4% of TRV GP V LLC's holdings, making the stock its largest position. TRV GP V LLC owned about 14.00% of Septerna as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in Septerna during the 4th quarter worth $185,000. Rhumbline Advisers purchased a new stake in shares of Septerna in the 4th quarter valued at about $458,000. New York State Common Retirement Fund acquired a new stake in shares of Septerna in the 4th quarter valued at about $32,000. Bank of New York Mellon Corp purchased a new position in Septerna during the 4th quarter worth approximately $872,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Septerna during the fourth quarter worth approximately $3,197,000.

Insider Activity

In other news, Director Alan Ezekowitz acquired 7,491 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average cost of $6.35 per share, with a total value of $47,567.85. Following the purchase, the director now directly owns 24,911 shares of the company's stock, valued at approximately $158,184.85. This trade represents a 43.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Gil M. Labrucherie bought 5,000 shares of the firm's stock in a transaction on Friday, February 21st. The shares were purchased at an average price of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the transaction, the chief financial officer now owns 30,000 shares of the company's stock, valued at $175,500. This represents a 20.00 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 74,346 shares of company stock valued at $439,670 in the last three months.

Septerna Trading Up 1.7 %

Shares of NASDAQ:SEPN traded up $0.10 during trading on Tuesday, reaching $5.97. The company had a trading volume of 190,514 shares, compared to its average volume of 434,484. Septerna, Inc. has a fifty-two week low of $4.17 and a fifty-two week high of $28.99. The firm's fifty day moving average price is $6.23.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.05. The firm had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.13 million. Research analysts forecast that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SEPN. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $50.00 target price on shares of Septerna in a report on Tuesday, February 11th. Wells Fargo & Company dropped their price objective on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating on the stock in a research note on Friday, March 28th.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.